Credit Woes Hitting Even Pharma
The pharmaceutical industry may take risks with R&D, but its disciplined approach to the balance sheet has helped insulate it from the rapidly spreading global credit mess. But even pharma will not be completely shielded
You may also be interested in...
New ‘growth equity’ focus at Novo A/S to fund late-stage and commercially focused life sciences companies
The combined specialty pharma company to be a leader in abuse-resistant pain meds.
Tax measures that provide cash and encourage investment in the biotech sector should be part of economic stimulus package, group says.